Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Series A companies: The class of 2024

An analysis of the technologies behind last year’s biotech series A raisers predicts progress in nanoparticles, CAR cell therapies, degraders and ADCs

January 28, 2025 1:04 AM UTC

At least 152 biotech companies attracted series A investments in 2024, collectively raising over $6.7 billion. While that level of activity was similar to 2023, the number of megarounds nearly doubled.

An analysis from BioCentury’s BCIQ database identified 23 companies that raised $100 million or more last year, up from 10-13 companies in each of the prior four years...

Get Unlimited Access
To view this item, login or register for a free account.
Or Purchase This Article